STING1 and melanoma: The nanoplatform could be degraded quickly in the mildly acidic and high H2O2 conditions characteristic of the TME, resulting in a burst release of Mn2+ from CMM‐DiR.[114b] After systemic administration, the Mn2+ coupled with targeted PTT elicited robust systemic antitumor immunity and enabled a durable tumor regression in multiple murine models, including primary, multinodular, recurrent, and metastatic B16‐F10 melanoma.[114b] These findings highlight the significant therapeutic potential of combining PTT with STING agonists to combat advanced and metastatic tumors effectively.